Clinical Trial Update: OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rituximab-optimized therapy with liposomal vincristine for elderly patients with CD20+ diffuse large B-cell lymphoma; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Marqibo (vincristine liposome)
• Rituximab (rituximab)

Snippet

Sponsor: Universität des Saarlandes | Conditions: CD20+ Aggressive B-Cell Lymphoma | Phase 3 | Status: COMPLETED